That's why we're hiring a Senior AI Scientist to lead this effort from the ground up ā defining our AI strategy, building the infrastructure and growing a team to match our ambition.
If that sounds like you, or someone you know, we'd love to hear from you.
š
www.allox.bio/careers/seni...
AI chemistry, co-folding methods (e.g. AlphaFold3, Boltz), FBDD and chemoproteomics hold the promise of generating binders against virtually any pocket or surface. But a binder is not a drug.
As the image above shows, the missing piece is the middle layer ā functional maps that tell you which binders have a high probability of functional impact. That's what we generate.
The numbers speak for themselves. We've now generated 10X more functional protein data than currently exists in the scientific literature, representing hundreds of thousands of biophysical measurements. In three years, we'll have generated another 10X more.
This data is our most valuable asset & we've only scratched the surface of what AI can do with it. Training models on functional maps at this scale opens up the possibility of predicting hotspots in silico, massively expanding our addressable target space & accelerating our drug discovery pipeline.
AI drug discovery has a data problem. We're fixing it.
At ALLOX, we've spent the last few years building something that didn't exist before: a platform that systematically maps functional hotspots at scale, measuring the effects of mutations on protein-protein interactions across the proteome.
